399 related articles for article (PubMed ID: 23948943)
21. Two mouse models of Alzheimer's disease accumulate amyloid at different rates and have distinct Aβ oligomer profiles unaltered by ablation of cellular prion protein.
Purro SA; Farmer M; Noble E; Sarell CJ; Powell M; Yip D; Giggins L; Zakka L; Thomas DX; Farrow M; Nicoll AJ; Walsh D; Collinge J
PLoS One; 2023; 18(11):e0294465. PubMed ID: 37976283
[TBL] [Abstract][Full Text] [Related]
22. The case for soluble Aβ oligomers as a drug target in Alzheimer's disease.
Hefti F; Goure WF; Jerecic J; Iverson KS; Walicke PA; Krafft GA
Trends Pharmacol Sci; 2013 May; 34(5):261-6. PubMed ID: 23582316
[TBL] [Abstract][Full Text] [Related]
23. Immunization with either prion protein fragment 95-123 or the fragment-specific antibodies rescue memory loss and neurodegenerative phenotype of neurons in olfactory bulbectomized mice.
Bobkova NV; Medvinskaya NI; Kamynina AV; Aleksandrova IY; Nesterova IV; Samokhin AN; Koroev DO; Filatova MP; Nekrasov PV; Abramov AY; Leonov SV; Volpina OM
Neurobiol Learn Mem; 2014 Jan; 107():50-64. PubMed ID: 24239620
[TBL] [Abstract][Full Text] [Related]
24. β-amyloid oligomers and prion protein: Fatal attraction?
Forloni G; Balducci C
Prion; 2011; 5(1):10-5. PubMed ID: 21150333
[TBL] [Abstract][Full Text] [Related]
25. Amyloid-beta oligomers increase the localization of prion protein at the cell surface.
Caetano FA; Beraldo FH; Hajj GN; Guimaraes AL; Jürgensen S; Wasilewska-Sampaio AP; Hirata PH; Souza I; Machado CF; Wong DY; De Felice FG; Ferreira ST; Prado VF; Rylett RJ; Martins VR; Prado MA
J Neurochem; 2011 May; 117(3):538-53. PubMed ID: 21352228
[TBL] [Abstract][Full Text] [Related]
26. Cellular prion protein as a receptor for amyloid-β oligomers in Alzheimer's disease.
Salazar SV; Strittmatter SM
Biochem Biophys Res Commun; 2017 Feb; 483(4):1143-1147. PubMed ID: 27639648
[TBL] [Abstract][Full Text] [Related]
27. Sialylated glycosylphosphatidylinositols suppress the production of toxic amyloid-β oligomers.
Nolan W; McHale-Owen H; Bate C
Biochem J; 2017 Aug; 474(17):3045-3058. PubMed ID: 28729427
[TBL] [Abstract][Full Text] [Related]
28. Cellular prion protein mediates the toxicity of beta-amyloid oligomers: implications for Alzheimer disease.
Nygaard HB; Strittmatter SM
Arch Neurol; 2009 Nov; 66(11):1325-8. PubMed ID: 19901162
[TBL] [Abstract][Full Text] [Related]
29. Development of Alkaline Phosphatase-Fused Mouse Prion Protein and Its Application in Toxic Aβ Oligomer Detection.
Tsukakoshi K; Kubo R; Ikebukuro K
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36498917
[TBL] [Abstract][Full Text] [Related]
30. Accumulation of cellular prion protein within β-amyloid oligomer plaques in aged human brains.
Takahashi RH; Yokotsuka M; Tobiume M; Sato Y; Hasegawa H; Nagao T; Gouras GK
Brain Pathol; 2021 Sep; 31(5):e12941. PubMed ID: 33624334
[TBL] [Abstract][Full Text] [Related]
31. Aβ induces its own prion protein N-terminal fragment (PrPN1)-mediated neutralization in amorphous aggregates.
Béland M; Bédard M; Tremblay G; Lavigne P; Roucou X
Neurobiol Aging; 2014 Jul; 35(7):1537-48. PubMed ID: 24602510
[TBL] [Abstract][Full Text] [Related]
32. Oligomeric Aβ-induced synaptic dysfunction in Alzheimer's disease.
Tu S; Okamoto S; Lipton SA; Xu H
Mol Neurodegener; 2014 Nov; 9():48. PubMed ID: 25394486
[TBL] [Abstract][Full Text] [Related]
33. Prions and Neurodegenerative Diseases: A Focus on Alzheimer's Disease.
Crestini A; Santilli F; Martellucci S; Carbone E; Sorice M; Piscopo P; Mattei V
J Alzheimers Dis; 2022; 85(2):503-518. PubMed ID: 34864675
[TBL] [Abstract][Full Text] [Related]
34. Alzheimer's amyloid-β oligomers rescue cellular prion protein induced tau reduction via the Fyn pathway.
Chen RJ; Chang WW; Lin YC; Cheng PL; Chen YR
ACS Chem Neurosci; 2013 Sep; 4(9):1287-96. PubMed ID: 23805846
[TBL] [Abstract][Full Text] [Related]
35. Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers II: Sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity.
Izzo NJ; Xu J; Zeng C; Kirk MJ; Mozzoni K; Silky C; Rehak C; Yurko R; Look G; Rishton G; Safferstein H; Cruchaga C; Goate A; Cahill MA; Arancio O; Mach RH; Craven R; Head E; LeVine H; Spires-Jones TL; Catalano SM
PLoS One; 2014; 9(11):e111899. PubMed ID: 25390692
[TBL] [Abstract][Full Text] [Related]
36. Synaptic changes in Alzheimer's disease and its models.
Pozueta J; Lefort R; Shelanski ML
Neuroscience; 2013 Oct; 251():51-65. PubMed ID: 22687952
[TBL] [Abstract][Full Text] [Related]
37. Alzheimer's disease brain-derived amyloid-β-mediated inhibition of LTP in vivo is prevented by immunotargeting cellular prion protein.
Barry AE; Klyubin I; Mc Donald JM; Mably AJ; Farrell MA; Scott M; Walsh DM; Rowan MJ
J Neurosci; 2011 May; 31(20):7259-63. PubMed ID: 21593310
[TBL] [Abstract][Full Text] [Related]
38. Cellular prion protein targets amyloid-β fibril ends via its C-terminal domain to prevent elongation.
Bove-Fenderson E; Urano R; Straub JE; Harris DA
J Biol Chem; 2017 Oct; 292(41):16858-16871. PubMed ID: 28842494
[TBL] [Abstract][Full Text] [Related]
39. Soluble Aβ levels correlate with cognitive deficits in the 12-month-old APPswe/PS1dE9 mouse model of Alzheimer's disease.
Zhang W; Hao J; Liu R; Zhang Z; Lei G; Su C; Miao J; Li Z
Behav Brain Res; 2011 Sep; 222(2):342-50. PubMed ID: 21513747
[TBL] [Abstract][Full Text] [Related]
40. LPYFDa neutralizes amyloid-beta-induced memory impairment and toxicity.
Granic I; Masman MF; Kees Mulder C; Nijholt IM; Naude PJ; de Haan A; Borbély E; Penke B; Luiten PG; Eisel UL
J Alzheimers Dis; 2010; 19(3):991-1005. PubMed ID: 20157254
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
